Regarding patents held by BIOGENERA, a patent has been granted outright in Argentina. This brings to a total of 56 fully-owned BIOGENERA patents that are approved outright, covering 46 countries globally, covering the MyGeneraTM platform, the drug BGA002 and five other drug candidates. […]
An important achievement has been achieved by the BIOGENERA Research Team regarding the scientific publication of a new article in the prestigious international journal “Cancers.” The article titled “Antigen MYCN Silencing by BGA002 Inhibits SCLC Progression Blocking mTOR Pathway and Overcomes Multidrug Resistance” describes the anti-tumor efficacy obtained in preclinical studies related to our new […]
An important achievement was achieved, concerning the publication of an article in the prestigious international journal “Cancers” entitled “MYCN Impact on High-Risk Neuroblastoma: From Diagnosis and Prognosis to Targeted Treatment” regarding the centrality of the MYCN oncogene in the pathological context of neuroblastoma. Specifically, the study highlights how MYCN affects High Risk Neuroblastoma cases, in […]
An important achievement has been achieved by the BIOGENERA Research Team regarding the scientific publication of an article in the prestigious international journal “Pharmaceutics.” The article titled “Precision Anti-Cancer Medicines by Oligonucleotide Therapeutics in Clinical Research Targeting Undruggable Proteins and Non-Coding RNAs” is about the importance of precision medicine in oncology. In particular, the study […]
An important achievement has been achieved by the BIOGENERA Research Team, concerning the scientific publication of an article in the prestigious international journal “Journal of Experimental & Clinical Cancer Research.” The article titled “The MYCN inhibitor BGA002 restores the retinoic acid response leading to differentiation or apoptosis by the mTOR block in MYCN-amplified Neuroblastoma” is […]
An important achievement has been achieved by the BIOGENERA Research Team, concerning the scientific publication of an article in the prestigious international journal “Cancer Research.” The article titled “A Novel MYCN-Specific Antigen Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma. The article is about the anti-tumor effects obtained in preclinical studies of BIOGENERA’s […]
